Associations - RB1 mutation

RB1 mutation RB1 mutation	Urothelial Cancer Urothelial Cancer	RB1 mutation RB1 mutation	Urothelial Cancer Urothelial Cancer	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
RB1 mutation RB1 mutation	Bladder Cancer Bladder Cancer	RB1 mutation RB1 mutation	Bladder Cancer Bladder Cancer	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
RB1 mutation RB1 mutation	Small Cell Lung Cancer Small Cell Lung Cancer	RB1 mutation RB1 mutation	Small Cell Lung Cancer Small Cell Lung Cancer	nivolumab Resistant: C3 – Early Trials	nivolumab Resistant: C3 – Early Trials
RB1 mutation RB1 mutation	Prostate Cancer Prostate Cancer	RB1 mutation RB1 mutation	Prostate Cancer Prostate Cancer	AST-2970 Resistant: C3 – Early Trials	AST-2970 Resistant: C3 – Early Trials
RB1 mutation RB1 mutation	Prostate Cancer Prostate Cancer	RB1 mutation RB1 mutation	Prostate Cancer Prostate Cancer	docetaxel Resistant: C3 – Early Trials	docetaxel Resistant: C3 – Early Trials
RB1 mutation RB1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	RB1 mutation RB1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	carboplatin + docetaxel Sensitive: C3 – Early Trials	carboplatin + docetaxel Sensitive: C3 – Early Trials
RB1 mutation RB1 mutation	Ovarian Cancer Ovarian Cancer	RB1 mutation RB1 mutation	Ovarian Cancer Ovarian Cancer	carboplatin + paclitaxel Resistant: C3 – Early Trials	carboplatin + paclitaxel Resistant: C3 – Early Trials
RB1 mutation RB1 mutation	Prostate Cancer Prostate Cancer	RB1 mutation RB1 mutation	Prostate Cancer Prostate Cancer	cyclophosphamide + dexamethasone Sensitive: C4 – Case Studies	cyclophosphamide + dexamethasone Sensitive: C4 – Case Studies
RB1 mutation RB1 mutation	Meningioma Meningioma	RB1 mutation RB1 mutation	Meningioma Meningioma	palbociclib Sensitive: D – Preclinical	palbociclib Sensitive: D – Preclinical
RB1 mutation RB1 mutation	Ovarian Cancer Ovarian Cancer	RB1 mutation RB1 mutation	Ovarian Cancer Ovarian Cancer	abemaciclib Resistant: D – Preclinical	abemaciclib Resistant: D – Preclinical
RB1 mutation RB1 mutation	Small Cell Lung Cancer Small Cell Lung Cancer	RB1 mutation RB1 mutation	Small Cell Lung Cancer Small Cell Lung Cancer	nivolumab + ipilimumab Resistant: D – Preclinical	nivolumab + ipilimumab Resistant: D – Preclinical